Skip to main content

Table 3 Treatment characteristics

From: The efficacy of multiple versus single hyaluronic acid injections: a systematic review and meta-analysis

Trial ID Molecular Weight Cross-Linked Production method Injection technique Injection regimen
Altman, 2004 High Yes Bio-HA NR Single 60 mg/3 ml injection of IA-HA or saline
Altman, 2009 High No Bio-HA Suprapatellar or infrapatellar approach 3 weekly injections of IA-HA (20 mg/2 ml) or saline
Arden, 2014 High Yes Bio-HA Lateral midpatellar, lateral upper-patellar or medial Single 3 ml injectionof IA-HA (60 mg/3 ml) or saline
Brandt, 2001 Moderate No Bio-HA NR 3 weekly injections of IA-HA (2 ml; 15 mg/ml) or saline (2 ml)
Chevalier, 2010 High Yes ADHA NR Single 6 ml injectionof IA-HA or saline
Creamer, 1994 Low No ADHA NR Single injection of HA (20 mg/2 ml) into one knee and saline (2 ml) into the other
Day, 2004 Low No ADHA Lateral or medial approach 5 weekly injections of 25 mg/2.5 ml IA-HA in a phosphate buffered solution or 2.5 ml vehicle or saline
DeCaria, 2012 Low No NR Anteromedial approach 3 weekly injections of IA-HA (2 ml of 20 mg/ml), or saline (1.2 ml of 0.001 mg/ml HA)
Diracoglu, 2009 High Yes ADHA NR 3 weekly injections of IA-HA or saline
Dixon, 1988 Low No ADHA NR Up to 11 injections of IA-HA (20 mg/2 ml) or placebo (0.2 mg sodium hyaluronate)
Henderson, 1994 Low No ADHA Medial approach 5 weekly injections of IA-HA (20 mg/2 ml) or saline
Huang, 2011 Low No ADHA NR 5 weekly injections of IA-HA (20 mg/2 ml) or saline
Huskisson, 1999 Low No ADHA NR 5 weekly injections of IA-HA (20 mg/2 ml) or saline
Jorgensen, 2010 Low No ADHA Lateral parapatellar approach 5 weekly injections of IA-HA (20 mg/2 ml) or saline
Karlsson, 2002 High Yes ADHA NR 3 weekly injections of IA-HA (Artzal, 2.5 ml or Synvisc, 2.0 ml) or saline
Kotevoglu, 2006 High Yes ADHA Anterolateral approach 3 weekly injections of IA-HA or saline
Lohmander, 1996 Low No ADHA NR 5 weekly injections of IA-HA (25 mg/2.5 ml) or saline
Lundsgaard, 2008 Low No ADHA Lateral midpatellar portal 4 weekly intra-articular injections of IA-HA 2 mL (Hyalgan, 10.3 mg/ml) versus physiological saline 20 ml (distention) versus physiological saline 2 ml
Navarro-Sarabia 2011 Low No Bio-HA NR 4 treatment cycles of 5 weekly injections of IA-HA or saline (2.5 ml)
Neustadt, 2005 Moderate No Bio-HA Lateral or medial approach 4 weekly injections of IA-HA (30 mg/2 ml), or 4 arthrocenteses without injection (control)
Petrella, 2006 Low no ADHA NR 3 weekly injections of IA-HA (20 mg/ml) or saline
Petrella, 2008 High No ADHA Medial approach 3 weekly injections of IA-HA or saline
Pham, 2004 NR NR NR NR 3 weekly injections of IA-HA or saline
Puhl, 1993 High No ADHA NR 5 weekly injections of IA-HA (25 mg/2.5 ml) or dilute IA-HA control(0.25 mg/2.5 ml HA)
Scale, 1994 High No ADHA NR Two intra-articular injections of IA-HA (2.0 ml) administered 2 weeks apart were compared with three intra-articular injections of IA-HA given 1 week apart vs saline (2.0 ml)
Sezgin, 2005 Moderate No Bio-HA NR 3 weekly injections of IA-HA (15 mg/ml) or saline
Strand, 2012 High Yes ADHA NR Single 3 ml injection of IA-HA (30 mg/3.0 ml) or saline
Tamir, 2001 High No Bio-HA NR 5 weekly injections of 20 mg IA-HA (10 mg/ml) or saline
van der Weegen, 2015 Low Yes Bio-HA NR 3 weekly injections of IA-HA (15 mg/ml) or saline
Wobig, 1998 High Yes ADHA NR 3 weekly injections of 2.0 ml IA-HA or saline
  1. ADHA Avian-derived hyaluronic acid, Bio-HA Biologically fermented hyaluronic acid, IA-HA Intra-articular hyaluronic acid, NA Not Applicable, NR Not Reported
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us